16956917

Source:http://linkedlifedata.com/resource/pubmed/id/16956917

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0017431, umls-concept:C0030705, umls-concept:C0035525, umls-concept:C0439230, umls-concept:C0524910, umls-concept:C0982327, umls-concept:C2603343
pubmed:issue	4
pubmed:dateCreated	2007-3-19
pubmed:abstractText	The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-10365720, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-10462387, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-11398104, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-11583749, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-12324553, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-12360468, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-12825172, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-14697814, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-14996676, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15057920, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15158341, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15163776, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15558712, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15751770, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15850469, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15854180, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15915461, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-15972867, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-16083709, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-16166797, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-16290907, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-16323137, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-16420512, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-17302371, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-1808228, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-7308988, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-7504073, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-7597443, http://linkedlifedata.com/resource/pubmed/commentcorrection/16956917-8834023
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/2985108R
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0017-5749
pubmed:author	pubmed-author:ChangWen-YuWY, pubmed-author:ChenShinn-CherngSC, pubmed-author:ChiuChang-FuCF, pubmed-author:ChuangWan-LongWL, pubmed-author:DaiChia-YenCY, pubmed-author:HouNai-JenNJ, pubmed-author:HsiehMing-YenMY, pubmed-author:HsiehMing-YuhMY, pubmed-author:HuangJee-FuJF, pubmed-author:LeeLi-PoLP, pubmed-author:LinZu-YauZY, pubmed-author:WangLiang-YenLY, pubmed-author:YuMing-LungML
pubmed:issnType	Print
pubmed:volume	56
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	553-9
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:16956917-Adult, pubmed-meshheading:16956917-Antiviral Agents, pubmed-meshheading:16956917-Drug Administration Schedule, pubmed-meshheading:16956917-Drug Therapy, Combination, pubmed-meshheading:16956917-Female, pubmed-meshheading:16956917-Follow-Up Studies, pubmed-meshheading:16956917-Genotype, pubmed-meshheading:16956917-Hepacivirus, pubmed-meshheading:16956917-Hepatitis C, Chronic, pubmed-meshheading:16956917-Humans, pubmed-meshheading:16956917-Interferon-alpha, pubmed-meshheading:16956917-Male, pubmed-meshheading:16956917-Middle Aged, pubmed-meshheading:16956917-Polyethylene Glycols, pubmed-meshheading:16956917-RNA, Viral, pubmed-meshheading:16956917-Recombinant Proteins, pubmed-meshheading:16956917-Recurrence, pubmed-meshheading:16956917-Ribavirin, pubmed-meshheading:16956917-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
pubmed:affiliation	Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study